Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00479349
Status:
COMPLETED
Last Update Posted:
2009-07-07
First Post:
2007-05-24
Brief Title:
Study Evaluating the Safety Pharmacokinetics and Pharmacodynamics of SAM-531
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
An Ascending Multiple Dose Study of the Safety Pharmacokinetics PK and Pharmacodynamics PD of SAM-531 Administered Orally to Healthy Japanese Young Male and Elderly Subjects
Status:
COMPLETED
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the safety and tolerability of ascending multiple oral doses of SAM-531 an investigational drug in healthy Japanese young male and elderly subjectsTo provide the pharmacokinetics PK and pharmacodynamics PD profiles of multiple oral doses of SAM-531 in healthy Japanese young male and elderly subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None